Multiple Myeloma

Latest News

$A panel of experts discusses the management of adverse effects including dysgeusia and infections among patients who received bispecific therapies for relapsed/refractory multiple myeloma in the context of a clinical case.$

November 23rd 2023

Managing Toxicity Following Bispecific Therapy in R/R Multiple Myeloma

By Russ Conroy

A panel of experts discusses the management of adverse effects including dysgeusia and infections among patients who received bispecific therapies for relapsed/refractory multiple myeloma in the context of a clinical case.

Latest Videos

A panel of 4 experts on multiple myeloma

Collaborative Education for CAR T-Cell Therapy

Unmet Needs and Future Perspectives for CAR T-Cell Therapy in R/R MM

Cesar Rodriguez, MD, and Frits van Rhee, MD, PhD

Adverse Event Considerations for DARA-VRd in NDMM

Long-Term Follow-up with Teclistamab in R/R MM: Updates from MajesTEC-1

Key Efficacy Data from PERSEUS in Newly Diagnosed Multiple Myeloma

Updates From the Phase 2 MonumenTAL-2 Study Investigating Talquetamab in R/R MM

Improving Access for Patients Receiving CAR T-Cell Therapy

Educating Patients on Complications Associated with CAR T-Cell Therapy

Managing Cytopenias and HLH/MAS Following CAR T-Cell Therapy

Supportive Care Strategies for CAR T-Cell Therapy Recipients

CME Content

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Iowa Oncology Society

Marla D. Lipsyc-Sharf, MD; Sheila Donnelly, MD

Video

Show Me the Data™: Post-TKI Sequencing in EGFR-Mutated NSCLC—Optimizing Current Strategies and Preparing for New Treatment Modalities

Christine M. Lovly, MD, PhD, FASCO; Xiuning Le, MD, PhD; Hossein Borghaei, DO, MS; Lyudmila Bazhenova, MD

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Texas Society of Clinical Oncology

Marla D. Lipsyc-Sharf, MD; Parth Khade, MD

Video

22nd Annual International Symposium on Melanoma and Other Cutaneous Malignancies®

Omid Hamid, MD; Sapna Patel, MD

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | North Carolina Oncology Association

Marla D. Lipsyc-Sharf, MD; Yan Ji, MD

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | New Mexico Society of Clinical Oncology

Marla D. Lipsyc-Sharf, MD; Kimberly Ku, MD

Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Ghassan Abou-Alfa, MD, MBA

Multimedia

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

Hope S. Rugo, MD, FASCO; Neil M. Iyengar, MD; Komal Jhaveri, MD, FACP

Multimedia

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Rebecca Shatsky, MD; Kelly McCann, MD, PhD; Michelle L. Taylor, ANP-BC

Video

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Shubham Pant, MD, MBBS

Video

Proactive Adverse Event Management for HER2+ BTC Treatments

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Rachna T. Shroff, MD, MS, FASCO

Multimedia

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

Yana G. Najjar, MD; Douglas B. Johnson, MD, MSCI; Rahul A. Sheth, MD, FSIR

Video

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

Cindy Neunert, MD, MSCS; Hanny Al-Samkari, MD; Joseph Shatzel, MD, MCR

Video

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD

Video

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Jonathan W. Goldman, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhD

Video

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

Video

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

John H. Strickler, MD; Stacey A. Cohen, MD; Aparna Parikh, MD; Kanwal P.S. Raghav, MBBS, MD

Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Eileen M. O’Reilly, MD; E. Gabriela Chiorean, MD, FASCO; Michael J. Pishvaian, MD, PhD; Brian Wolpin, MD, MPH

Video

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Gail J. Roboz, MD; Hagop Kantarjian, MD; Catherine Lai, MD, MPH; Amer Zeidan, MBBS, MHS

Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Balazs Halmos, MD, MS; Enriqueta Felip, MD, PhD; Julia Rotow, MD

Video

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Rami Komrokji, MD; Gabriela Hobbs, MD; John Mascarenhas, MD; Naveen Pemmaraju, MD

Multimedia

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD

Multimedia

Breaking Down the Rationale for Targeting TROP2 in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Audio

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Hossein Borghaei, DO, MS

Video

Cross-Disease Integration of Immunotherapy Innovations

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Video

Optimizing Treatment for Biliary Tract Cancers

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Multimedia

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCO

Video

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Ana C. Garrido-Castro, MD; Pedram Razavi, MD, PhD

Multimedia

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Video

(CME Track) Live Tumor Board: Squamous Cell Carcinoma of the Head & Neck - Post-CRT Decisions in the Locally Advanced Setting

Quynh-Thu Le, MD, FACR, FASTRO; Vlad C. Sandulache, MD, PhD

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Rocky Mountain Oncology Society

Seth A. Wander, MD, PhD; Kara M. Schenk, MD

Virtual Event

Oncology Town Hall - Translating the Latest Updates Into the Care of Patients With AML in Community Practices

April 9, 2026

In-Person + Virtual Event

11th Annual School of Gastrointestinal Oncology® (SOGO®)

April 11, 2026

In-Person + Virtual Event

Tumor Board: Clinical Integration of Molecular Profiling in Glioma - Transforming the Use of Targeted Therapy

April 20, 2026

Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Rebecca Heist, MD, MPH; Alex A. Adjei, MD, PhD, FACP; Sandip Patel, MD, FASCO; Jeremy Segal, MD, PhD

Video

Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies

Vinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA; Stephen J. Bagley, MD, MSCE; Angela Waanders, MD, MPH, MS

$Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma$

Video

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

Video

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Joyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCO

Multimedia

Establishing the Rationale for ADC and ICI Combinations in TNBC

Virginia Kaklamani, MD, DSc; Tiffany A. Traina, MD, FASCO

Multimedia

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc

Multimedia

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Video

Broadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular Carcinoma

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Audio

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Misty D. Shields, MD, PhD

Multimedia

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCO

Audio

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Giannis Mountzios ΜD, PhD

Video

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Multimedia

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Imaging Matters: Decoding PSMA PET for Better Decision-Making

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

More News

A panel of 4 experts on multiple myeloma seated at a long table

Toxicities From GPRC5D-Targeting Therapies in Multiple Myeloma

ByAjai Chari, MD,Brea C. Lipe, MD,Binod Dhakal, MD, MS,Jeffrey V. Matous, MD

November 21st 2023

The panel continues their discussion on adverse effect management with a focus on GPRC5D-targeting bispecific antibodies in multiple myeloma.

MM: Managing Toxicities From BCMA-Targeting Bispecific Antibodies

ByAjai Chari, MD,Brea C. Lipe, MD,Binod Dhakal, MD, MS,Jeffrey V. Matous, MD

November 21st 2023

Multiple myeloma specialists discuss the management of toxicities from BCMA-targeting bispecific antibodies.

Managing AEs in Multiple Myeloma: Dosing and Prophylactic Strategies

BySagar Lonial, MD, FACP, FASCO,Luciano Costa, MD, PhD,Cesar Rodriguez, MD,Donna Catamero, ANP-BC, OCN, CCRC

November 21st 2023

Key opinion leaders share their insight on managing adverse events in myeloma treatment, including dose adjustments and prophylactic strategies to improve outcomes and patient quality of life.

Craig Cole, MD, an expert on multiple myeloma, presenting slides

Cross Q&A: Role of Belantamab Mafodotin in MM

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

November 17th 2023

The panel discusses the efficacy of belantamab mafoditin and where the treatment fits in the multiple myeloma treatment landscape.

Treatment Recommendations for Relapsed Multiple Myeloma

ByONCOLOGY Staff

November 16th 2023

Experts in the multiple myeloma space met to discuss the treatment and monitoring after bispecific antibodies.

Bispecific-Based Combinations Under Evaluation for Patients with RRMM

ByCarolina D. Schinke, MD,Joselle Cook, M.B.B.S,Luciano Costa, MD, PhD,Binod Dhakal, MD, MS

November 16th 2023

Joselle Cook, M.B.B.S., and Luciano Costa, MD, note promising trials investigating combination bispecific antibody therapies for patients with relapsed/refractory multiple myeloma.

Teclistamab plus Nirogacestat in RRMM: The MAJESTEC-2 Study

ByCarolina D. Schinke, MD,Joselle Cook, M.B.B.S,Luciano Costa, MD, PhD,Binod Dhakal, MD, MS

November 16th 2023

Drs Luciano Costa and Binod Dhakal discuss combining bispecific antibodies with gamma secretase inhibitors for the treatment of relapsed/refractory multiple myeloma, but trials show limited benefit and added toxicity; more promising are combinations with immunomodulators like isatuximab.

Adverse Events With Bispecific Therapy: Dysgeusia, Skin, and Nail Changes

BySagar Lonial, MD, FACP, FASCO,Luciano Costa, MD, PhD,Cesar Rodriguez, MD,Donna Catamero, ANP-BC, OCN, CCRC

November 14th 2023

Overview of challenges in managing adverse events associated with bispecific therapy in multiple myeloma, including dysgeusia, skin toxicity, and nail changes patients may experience.

Managing Adverse Effects from Bispecific Antibodies in Multiple Myeloma

ByAjai Chari, MD,Brea C. Lipe, MD,Binod Dhakal, MD, MS,Jeffrey V. Matous, MD

November 14th 2023

Comprehensive insights on the management of adverse effects from bispecific antibodies in the treatment of multiple myeloma.

Bispecific Therapies in Multiple Myeloma: Impact on Real-World Practice

BySagar Lonial, MD, FACP, FASCO,Luciano Costa, MD, PhD,Cesar Rodriguez, MD,Donna Catamero, ANP-BC, OCN, CCRC

November 14th 2023

Experts share how the availability of three new bispecific therapies has transformed myeloma patient care, offering a lifeline to those previously without treatment options and showcasing positive responses in various patient populations.

Dosing Considerations for Bispecific Antibodies in MM

ByAjai Chari, MD,Brea C. Lipe, MD,Binod Dhakal, MD, MS,Jeffrey V. Matous, MD

November 14th 2023

Expert oncologists discuss dosing considerations for bispecific antibodies in the treatment of patients with multiple myeloma.

Treatment Updates and Key Highlights in Multiple Myeloma and CML

ByONCOLOGY Staff

November 13th 2023

Karmanos Cancer Institute and Cleveland Clinic gave presentations regarding treatment of multiple myeloma and chronic myeloid leukemia in the latest Face Off.

DREAMM-3: Belantamab Mafodotin in Patients With Relapsed/Refractory MM

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

November 10th 2023

Craig Cole, MD, reviews data from DREAMM-3 on the efficacy and safety of single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma.

Faiz Anwer, MD, an expert on multiple myeloma, presenting slides

Cross Q&A: Clinical Application of Ixa-Len-Dex for Patients With MM

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

November 10th 2023

Experts on multiple myeloma discuss the clinical applications of ixazomib-lenalidomide-dexamethasone combination therapy.

Teclistamab Plus Talquetamab in RRMM: Data from the RedirecTT-1 Study

ByCarolina D. Schinke, MD,Joselle Cook, M.B.B.S,Luciano Costa, MD, PhD,Binod Dhakal, MD, MS

November 9th 2023

Joselle Cook, M.B.B.S., discusses the RedirecTT-1 trial combining teclistamab and talquetamab for patients with relapsed/refractory multiple myeloma, noting high response rates even in high-risk myeloma but concerns about long-term resistance.

Talquetamab in RRMM: Results From MonumenTAL-1

ByCarolina D. Schinke, MD,Joselle Cook, M.B.B.S,Luciano Costa, MD, PhD,Binod Dhakal, MD, MS

November 9th 2023

Dr Binod Dhakal discusses response rates and toxicities seen with recently approved bispecific antibodies talquetamab in patients with heavily pretreated multiple myeloma, noting high response rates even after CAR-T, but also unique side effects.

Bispecific Therapies in RRMM: Teclistamab, Talquetamab, and Elranatamab Updates

BySagar Lonial, MD, FACP, FASCO,Luciano Costa, MD, PhD,Cesar Rodriguez, MD,Donna Catamero, ANP-BC, OCN, CCRC

November 7th 2023

Insight into the latest updates on three approved bispecific therapies in the context of relapsed and refractory multiple myeloma, including teclistamab, talquetamab, and elranatamab, discussing response rates, administration, and side effects.

Recent Data on Bispecific Antibodies in Multiple Myeloma

ByAjai Chari, MD,Brea C. Lipe, MD,Binod Dhakal, MD, MS,Jeffrey V. Matous, MD

November 7th 2023

A review of clinical trial data on bispecific antibodies in multiple myeloma and clinical insights on how these medications have changed clinical practice.

Patient Scenario: Management of Multiple Myeloma With Talquetamab Therapy

BySagar Lonial, MD, FACP, FASCO,Luciano Costa, MD, PhD,Cesar Rodriguez, MD,Donna Catamero, ANP-BC, OCN, CCRC

November 7th 2023

Dive into a compelling case study showcasing the effective use of talquetamab therapy in the management of relapsed multiple myeloma, discussing responses, side effects, and treatment outcomes.

Multiple Myeloma Treatment: Patient Profiles

ByAjai Chari, MD,Brea C. Lipe, MD,Binod Dhakal, MD, MS,Jeffrey V. Matous, MD

November 7th 2023

The panel reviews the profiles of 2 patients with multiple myeloma and provides their initial thoughts regarding treatment approaches.

REMIX: Real-World Effectiveness of Ixazomib with Lenalidomide and Dexamethasone in MM

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

November 3rd 2023

Faiz Answer, MD, FACP, reviews data from the REMIX study on the real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma.

Jeffrey A. Zonder, MD, an expert on multiple myeloma

Cross Q&A: Retrospective Study of Patients With MM

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

November 3rd 2023

Experts in the field of multiple myeloma discuss data from a retrospective study on patients with multiple myeloma.

Treatment Options for Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

ByCarolina D. Schinke, MD,Joselle Cook, M.B.B.S,Luciano Costa, MD, PhD,Binod Dhakal, MD, MS

November 2nd 2023

Dr Luciano Costa discusses treatment options for patients with multiple myeloma with early vs late relapse, noting that those with early aggressive relapse have limited options and often rapidly exhaust available therapies, emphasizing the need for newer agents like bispecific antibodies.

Patient Case Presentation: A 47-Year-Old Man With Multiple Myeloma

ByCarolina D. Schinke, MD,Joselle Cook, M.B.B.S,Luciano Costa, MD, PhD,Binod Dhakal, MD, MS

November 2nd 2023

Binod Dhakal, MD, presents the case of a young man with aggressive relapsed multiple myeloma to the panel for discussion.

Evolving Treatment Paradigms in Relapsed/Refractory Multiple Myeloma

BySagar Lonial, MD, FACP, FASCO,Luciano Costa, MD, PhD,Cesar Rodriguez, MD,Donna Catamero, ANP-BC, OCN, CCRC

October 31st 2023

Join moderator Sagar Lonial, MD, FACP, and a panel of experts as they discuss recent updates in the management of relapsed and refractory multiple myeloma, exploring impact on clinical practice.